

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ozaki et al.

Serial No.: 09/214,881


Filed: June 7, 1999

For: DIAGNOSTIC DRUGS FOR AUTO  
IMMUNE DISEASE

Group Art Unit: 1644

Examiner: Patrick Nolan

Att'y Docket: 13240.0004.NPUS00

Client Docket: F5-01F03832/  
KA016-1 US RCEREQUEST FOR CONTINUED EXAMINATION (RCE)Commissioner for Patents  
Washington, D.C. 20231CERTIFICATE OF TRANSMISSION  
37 C.F.R. 1.8I hereby certify that this correspondence is being facsimile transmitted to  
the U.S. Patent and Trademark Office to (703) 746-5303 on the date  
below:27 SEP 02  
Date  
Signature

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the  
above identified application.

## 1. Submission required under 37 C.F.R. § 1.114

- a.  Previously submitted
  - i.  Consider the amendment(s)/reply under 37 C.F.R. § 1.116  
previously filed on .
  - ii.  Consider the arguments in the Appeal Brief or Reply Brief  
previously filed on .
  - iii.  Other
- b.  Enclosed
  - i.  Amendment/reply
  - ii.  Affidavit(s)/Declaration(s)
  - iii.  Information Disclosure Statement (IDS)

d9/10/02 G

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: § Group Art Unit: 1644  
 Ozaki et al. § Examiner: Patrick Nolan  
 Serial No.: 09/214,881 § Att'y Docket: 13240.0004.NPUS00  
 Filed: June 7, 1999 § Client Docket: F5-01F03832/  
 For: DIAGNOSTIC DRUGS FOR AUTO KA016-1 US RCE  
 IMMUNE DISEASE §

PRELIMINARY AMENDMENT

Commissioner for Patents  
 Washington, D.C. 20231

CERTIFICATE OF TRANSMISSION 37 C.F.R. 1.8	
I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office to (703) 746-5303 on the date below:	
<u>27 SEP 02</u> Date	 Signature

Sir:

Please amend this application as follows:

IN THE CLAIMS:

Please enter the following rewritten claim. A marked up version of the rewritten claim, and a clean version of all pending claims are attached at the end of this document.

*Sub H1* 6. (Three times amended) The kit of claim 4, wherein:  
 the polypeptide having an amino acid sequence homology of 90% or more with SEQ ID  
 NO:1 is selected from human, bovine, porcine, or rat HMG-1; and  
 the polypeptide having an amino acid sequence homology of 80% or more with SEQ ID  
 NO:2 is selected from human, bovine, porcine, chicken, mouse, or rat HMG-2.